Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes |
| |
| Authors: | Siitonen Timo,Timonen Timo,Juvonen Eeva,Terävä Venla,Kutila Anu,Honkanen Tuomo,Mikkola Maija,Hallman Heikki,Kauppila Marjut,Nyländen Pirkko,Poikonen Eira,Rauhala Auvo,Sinisalo Marjatta,Suominen Merja,Savolainen Eeva-Riitta,Koistinen Pirjo Pirjo Koistinen for the Finnish Leukemia Group |
| |
| Affiliation: | Department of Internal Medicine, Oulu University Hospital, OYS, Finland. timo.siitonen@ppshp.fi |
| |
| Abstract: | Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to toxicity. According to international working group criteria, three patients (16%) responded to treatment. No correlation between VPA serum level, histone acetylation or clinical response was observed. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
